Head-To-Head Analysis: Qilian International Holding Group (NASDAQ:QLI) & ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ:CFRXGet Rating) and Qilian International Holding Group (NASDAQ:QLIGet Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

58.4% of ContraFect shares are owned by institutional investors. Comparatively, 0.1% of Qilian International Holding Group shares are owned by institutional investors. 3.6% of ContraFect shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ContraFect and Qilian International Holding Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraFect 0 0 3 0 3.00
Qilian International Holding Group 0 0 1 0 3.00

ContraFect presently has a consensus target price of $9.00, indicating a potential upside of 131.96%. Given ContraFect’s higher possible upside, analysts clearly believe ContraFect is more favorable than Qilian International Holding Group.

Risk & Volatility

ContraFect has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500.

Earnings and Valuation

This table compares ContraFect and Qilian International Holding Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraFect N/A N/A -$20.28 million ($0.56) -6.93
Qilian International Holding Group $57.10 million 1.10 $3.15 million N/A N/A

Qilian International Holding Group has higher revenue and earnings than ContraFect.

Profitability

This table compares ContraFect and Qilian International Holding Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraFect N/A -46.04% -31.12%
Qilian International Holding Group N/A N/A N/A

Summary

ContraFect beats Qilian International Holding Group on 5 of the 9 factors compared between the two stocks.

About ContraFect (Get Rating)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

About Qilian International Holding Group (Get Rating)

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.